Stage ivb prostate cancer ajcc v8 Trials in Creve Coeur, United States
Conditions / Stage ivb prostate cancer ajcc v8 / Creve Coeur, United States
Stage ivb prostate cancer ajcc v8 is a medical condition with active clinical research programs worldwide.
10 total trials for this combination
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06632977 | Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial | RECRUITING | PHASE2 |
| NCT05241860 | Testing Interruption of Hormonal Medications in Patients Responding Exceptionally to Therapy for Metastatic Prostate Cancer, (A-DREAM) | ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT04423211 | Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging | RECRUITING | PHASE3 |
| NCT06931340 | Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial | RECRUITING | PHASE3 |
| NCT03317392 | Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis | ACTIVE_NOT_RECRUITING | PHASE1/PHASE2 |
| NCT05053152 | Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study | RECRUITING | PHASE2 |
| NCT04071236 | Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy | RECRUITING | — |
| NCT03678025 | Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer | RECRUITING | PHASE3 |
| NCT05828082 | Testing the Effect of M1774 on Hard-to-Treat Refractory SPOP-mutant Prostate Cancer | ACTIVE_NOT_RECRUITING | — |
| NCT03866382 | Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors | RECRUITING | — |